Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Largest number of cancers was projected to result from abdomen and pelvic CT in adults, reflecting 37 percent of those 103,000 cancers.